Synonyms: compound 34 [PMID: 25953512] | Dayvigo® | E-2006 | E2006
lemborexant is an approved drug (FDA (2019))
Compound class:
Synthetic organic
Comment: Lemborexant is an orally active, dual orexin receptor antagonist (DORA) [2].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Lemborexant (E2006) was advanced to Phase 3 clinical trial for insomnia (NCT02783729). In this trial lemborexant was compared against the approved GABAA receptor agonist, zolpidem, which is used to treat insomnia (and both against matched placebos). FDA approval as a treatment for insomnia was granted in December 2019. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02783729 | Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1) | Phase 3 Interventional | Eisai Inc. |